Statistical analysis
NSCLC, skin toxicity, skin toxicities
SKIN TOXICITIES, SKIN TOXICITY, NSCLC
We planned to include 40 patients with NSCLC in this trial. The sample size was calculated using a one‐sample binomial test. In the ARCHER1042 trial, the incidence of Grade ≥2 skin toxicity during 8 weeks of dacomitinib initiation was 46% in the placebo group and 23% in the doxycycline prophylaxis group, respectively.Regarding the primary endpoint, the incidence of Grade ≥2 skin toxicities in the initial 8 weeks of dacomitinib treatment was calculated, and a 90% confidence interval (CI) was estimated based on the Wald method. The 95% CI was calculated for the incidence of dose reduction with dacomitinib. The survival curve of PFS was estimated using the Kaplan–Meier method, and the 95% CI of the median PFS and yearly PFS rates were estimated using the Brookmeyer and Crowley method and Greenwood method, respectively. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for all statistical analyses.